光化性角化病治疗市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

市场按治疗类型(外用药物(氟尿嘧啶、咪喹莫特、Ingenol Mebutate、其他药物)、程序(光动力疗法、激光、其他程序))、最终用户和地理位置进行细分。

市场快照

Actinic Keratosis Treatment Market Overview
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.3 %
Actinic Keratosis Treatment Market Major Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

预计光化性角化病治疗市场在预测期内的复合年增长率为 5.3%。光化性角化病是在皮肤上形成的粗糙且经常凹凸不平的斑块或病变。这种情况有时称为日光性角化病或老年性角化病,它缓慢扩大,通常除了皮肤上的斑块或小斑点外没有任何迹象或症状。这些斑块需要数年时间才能形成,通常首先出现在 40 岁以上的人群中。光化性角化病更常见于眼睛浅色、皮肤白皙、头发呈红色或金色的老年人,这些人容易燃烧,晒得不好。一些光化性角化病可能会发展成一种称为鳞状细胞癌 (SCC) 的侵袭性皮肤癌。鳞状细胞癌 (SCC) 的进展可能表现为生长、不适/压痛和持续性溃疡或出血。

根据 J. Welzel 等人在 2019 年英国皮肤病学杂志上发表的研究报告,估计超过 50% 的浅肤色人群在其一生中受到光化性角化病的影响。光化性角化病是美国患者咨询皮肤科医生的第三大常见因素。此外,根据皮肤癌基金会,每年有超过 15,000 名美国人死于鳞状细胞癌。

此外,光化性角化病患病率的增加、对微创手术的需求不断增长以及新疗法研发的不断增加是光化性角化病治疗市场的关键驱动因素。

报告范围

根据报告的范围,光化性角化病是皮肤上的粗糙、鳞状斑块,是由于多年暴露于太阳辐射而形成的。它常见于面部、嘴唇、耳朵、手背、前臂、头皮或颈部。光化性角化病治疗市场按治疗、最终用户和地理划分。

By Therapy
Topical Medications
Fluorouracil
Imiquimod
Ingenol Mebutate
Other Medications
Procedures
Photodynamic Therapy
Laser
Other Procedures
By End User
Hospitals and Oncology Centers
Dermatology Clinics
Other End users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

外用药物部分预计将在光化性角化病治疗市场占据主要市场份额

外用药物部分在光化性角化病治疗市场中占有重要的市场份额,由于产品易于获得、目标特异性高且疤痕风险较低,预计在预测期内将显示出类似的趋势。美国食品和药物管理局 (FDA) 批准的一些用于治疗光化性角化病的药物是局部氟尿嘧啶、咪喹莫特、双氯芬酸、甲基丁烯醇和药物联合治疗。根据英国医学杂志 2019 年发表的研究报告,在英格兰,光化性角化病的患病率在 40 岁以上的男性中约为 15%,在女性中约为 5.9%,男性和女性的这一患病率分别上升至 34.1% 和 18.2% ,分别在 70 岁以上的患者中。光化性角化病被认为是癌前病变,因为皮肤鳞状细胞癌可能由光化性角化病引起。随着光化性角化病数量的增加,发生鳞状细胞癌的机会增加。此外,有前景的管道药物和联合治疗的高度采用是局部用药领域的关键驱动因素。

Actinic Keratosis Treatment Market Trends

北美预计将在市场上占有重要份额,预计在预测期内也将如此

由于对该地区光化性角化病的发生和相关鳞状细胞癌风险的认识不断提高,预计北美将在全球光化性角化病治疗市场占据主要市场份额。据美国皮肤病学会估计,每年有超过 4000 万美国人患上光化性角化病 (AK)。此外,在 40 岁以上的美国人中,约 60% 的光化性角化病易于发展为具有至少 1 个光化性角化病病变。此外,完善的医疗保健基础设施和不断增加的医疗保健支出也在很大程度上推动了整个区域市场的增长。

Actinic Keratosis Treatment Market Outlook

竞争格局

光化性角化病治疗市场具有综合竞争力,由几个主要参与者组成。在光化性角化病治疗市场上运营的一些知名企业包括 Bausch Health Companies Inc、LEO Pharma A/S、Almirall, SA、Biofrontera AG、Sun Pharmaceutical Industries Limited、3M Company、Galderma SA、Alma Lasers、Novartis AG 和 Hill Dermaceuticals , 公司

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Actinic Keratosis Worldwide

      2. 4.2.2 Growing Demand for Minimally Invasive Procedures

      3. 4.2.3 Favorable Reimbursement Policies

    3. 4.3 Market Restraints

      1. 4.3.1 Risk Factors Associated With Available Treatment Options

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Therapy

      1. 5.1.1 Topical Medications

        1. 5.1.1.1 Fluorouracil

        2. 5.1.1.2 Imiquimod

        3. 5.1.1.3 Ingenol Mebutate

        4. 5.1.1.4 Other Medications

      2. 5.1.2 Procedures

        1. 5.1.2.1 Photodynamic Therapy

        2. 5.1.2.2 Laser

        3. 5.1.2.3 Other Procedures

    2. 5.2 By End User

      1. 5.2.1 Hospitals and Oncology Centers

      2. 5.2.2 Dermatology Clinics

      3. 5.2.3 Other End users

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Bausch Health Companies Inc

      2. 6.1.2 LEO Pharma A/S

      3. 6.1.3 Almirall, S.A.

      4. 6.1.4 Biofrontera AG

      5. 6.1.5 Sun Pharmaceutical Industries Limited

      6. 6.1.6 3M Company

      7. 6.1.7 Galderma SA

      8. 6.1.8 Alma Lasers

      9. 6.1.9 Novartis AG

      10. 6.1.10 Hill Dermaceuticals, Inc

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The undefined market is studied from 2018 - 2026.

The undefined is growing at a CAGR of 5.3% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Bausch Health Companies Inc, LEO Pharma A/S, Almirall, S.A., Biofrontera AG, Sun Pharmaceutical Industries Limited are the major companies operating in undefined.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!